CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 36,223	$ 40,992
Prepaid expenses and other current assets	2,249	2,531
Research and development incentives receivables	1,562	1,497
Total current assets	40,034	45,020
Property and equipment, net	91	137
Operating lease right of use assets, net	108	244
Intangible assets, net	381	516
Total assets	40,614	45,917
Current liabilities:
Accounts payable	3,226	1,333
Accrued expenses	2,046	2,026
Operating lease liabilities - current	0	202
Other current liabilities	905	741
Total current liabilities	6,177	4,302
Warrant liabilities - non-current	21	38
Other non-current liabilities	362	661
Total liabilities	6,560	5,001
Commitments and contingencies (Note 16)
Shareholders' Equity
Ordinary shares, par value 0.003 per share; 795,484,404 shares issued at September 30, 2025 (December 31, 2024: 775,728,034)	3,145	3,135
Additional paid-in capital	551,018	549,622
Accumulated deficit	(507,538)	(501,018)
Accumulated other comprehensive loss	(12,571)	(10,823)
Total shareholders' equity	34,054	40,916	$ 60,969
Total liabilities and shareholders' equity	$ 40,614	$ 45,917

Current portion of research and development incentives receivables.

No definition available.

Name:	mreo_ResearchAndDevelopmentIncentivesReceivablesCurrent
Namespace Prefix:	mreo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).